Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
ProZinc is a protamine zinc insulin (PZI) formulation approved for the management of diabetes mellitus in cats and dogs. It contains recombinant human insulin combined with protamine and zinc to prolong its duration of action. As an intermediate- to long-acting insulin, ProZinc helps maintain stable blood glucose levels and reduce the clinical signs of diabetes, including polyuria, polydipsia, weight loss, and lethargy. It is administered subcutaneously and is designed for once- or twice-daily dosing based on the patient’s glucose monitoring results and clinical response.
ProZinc is administered by subcutaneous injection using a U-40 insulin syringe. Dosing must be individualized by a veterinarian, with a typical starting dose for cats at 0.1 to 0.3 units/kg every 12 hours, and for dogs at 0.2 to 0.5 units/kg once or twice daily, depending on the clinical condition and blood glucose readings. Shake the vial gently until uniformly milky before withdrawing the dose. Rotate injection sites to minimize irritation. Blood glucose levels and clinical signs should be monitored regularly to guide dose adjustments. Do not switch between U-40 and U-100 syringes, as dosing errors may occur.
Each mL of ProZinc contains:
Recombinant human insulin 40 units
Protamine sulfate
Zinc oxide
Glycerol, phenol, and water for injection as stabilizing and preservative agents
The product is a sterile, aqueous suspension and should be stored refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze or expose to direct sunlight.
ProZinc is contraindicated in:
Animals experiencing episodes of hypoglycemia
Patients with known hypersensitivity to any of the formulation components
Situations requiring rapid-acting insulin (e.g., diabetic ketoacidosis without concurrent short-acting insulin therapy)
Careful monitoring is essential during the initiation and adjustment phases of insulin therapy. Underdosing may result in poor glycemic control, while overdosing may cause life-threatening hypoglycemia, presenting as weakness, disorientation, seizures, or coma. Changes in diet, exercise, or concurrent medications may require dose adjustments. ProZinc should not be mixed with other insulins or administered intravenously. Clients should be trained in proper handling, injection technique, and signs of insulin-related complications.
Potential side effects include:
Hypoglycemia (most serious and common)
Injection site reactions
Somogyi effect (rebound hyperglycemia following hypoglycemia)
Rare: insulin resistance, allergic reactions, or lipodystrophy at injection sites